Bridgeway Capital Management’s Anika Therapeutics ANIK Stock Holding History

Bridgeway Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$256K	Hold	17,500	–	–	﹤0.01%	1005
2026 Q1	$254K	Hold	17,500	–	–	0.01%	975
2025 Q4	$168K	Hold	17,500	–	–	﹤0.01%	1051
2025 Q3	$165K	Hold	17,500	–	–	﹤0.01%	1047
2025 Q2	$185K	Buy	+17,500	New	+$221K	﹤0.01%	976
2015 Q1	–	Sell	-18,339	Closed	-$747K	–	1476
2014 Q4	$747K	Hold	18,339	–	–	0.02%	885
2014 Q3	$672K	Sell	18,339 -200	-1%	-$8.64K	0.02%	941
2014 Q2	$859K	Sell	18,539 -16,100	-46%	-$716K	0.02%	836
2014 Q1	$1.42M	Sell	34,639 -62,050	-64%	-$2.31M	0.04%	619
2013 Q4	$3.69M	Buy	96,689 +50	+0.1%	+$1.54K	0.11%	204
2013 Q3	$2.31M	Buy	96,639 +200	+0.2%	+$4.49K	0.08%	362
2013 Q2	$1.64M	Buy	+96,439	New	+$1.39M	0.07%	426

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Bridgeway Capital Management's ANIK Position: Q2 2026 in Review

Bridgeway Capital Management held its Anika Therapeutics (ANIK) position steady in Q2 2026 at 17,500 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #1005.

Bridgeway Capital Management first reported a position in ANIK in Q2 2013 and has held it in 12 quarters since. The position peaked at $3.69M in Q4 2013. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

Bridgeway Capital Management held 17,500 shares of Anika Therapeutics worth $256K as of Q2 2026.
Bridgeway Capital Management left its Anika Therapeutics share count unchanged in Q2 2026.
Anika Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1005 holding.
Bridgeway Capital Management first reported a position in Anika Therapeutics in Q2 2013 and has held it in 12 quarters since.
Bridgeway Capital Management's Anika Therapeutics position peaked at $3.69M in Q4 2013.
133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.